Sort by
Refine Your Search
-
motivation with proactive and independent work ethic Strong quantitative analysis skills; experience with programming statistical software (e.g., R) Experience with social network analysis is an advantage
-
, scanning and transmission electron microscopy, nano/micro-CT, mathematical modelling and many others. All of our projects are based on large network of local and international collaborators. This offers
-
: The research group of prof. Michal Masařík is a biomedical laboratory dedicated to exploring the molecular mechanisms that drive cancer progression, with a particular emphasis on the tumour microenvironment (TME
-
programming is welcomed Experience with social network analysis is an advantage but not required Experience with school interventions is an advantage but not required What We Offer A supportive, lively research
-
. Further, the applicant will be able to pursue their independent research and collaborate with other members of the department and at the Faculty of Informatics. A broader networking connection is available
-
ranked in Q1 according to Web of Science. Specific qualifications include: PhD in cell biology, molecular biology, or a related field Experience with stem cell culture and differentiation, preferably with
-
Mechanobiology section of Michal Masarik Laboratory, Faculty of Medicine, Masaryk University (Brno, Czech Republic) investigates how cytoskeletal organization and cellular mechanics influence cancer cell
-
Neurology at Masaryk University. The goal of our research group is to create robust computational frameworks with which to better understand how information is processed across the vast range of scales
-
of Masaryk University, Brno, Czech Republic invites excellent scientists to apply for a two-year POSTDOC POSITION in Cell Signaling Description: Postdoctoral position is available in laboratory of Pavel Krejci
-
hyperactivation of growth-controlling signalling pathways reshapes cellular signalling networks and influences the response of malignant melanoma to immunotherapy and targeted therapy with BRAF and MEK inhibitors